NCT02675452 2025-07-09
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Phase 1 Terminated
Amgen
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University